qiagen q3 2019

QIAGEN to report results for Q3 and first nine months of 2019. “We aremaintaining a sharp focus on operating efficiencies and disciplined capitalallocation to support growth and increase returns. Further information will be provided when QIAGEN plans to report results for the third quarter and first nine months of 2019 on October 30, 2019. Preliminary Q3 2019 sales of about 3% CER growth (vs.~4 … En este caso se trata de QIAGEN N.V.’s QGEN third-quarter 2019 adjusted earnings per share (EPS) were 36 cents, up 2.9% year over year.The figure beat the Zacks Consensus Estimate by the same magnitude. Total sales growth was about 6% CER excluding China sales. QIAGEN reports full results for third quarter and first nine months of 2019 Q3 2019 sales in line with October 7 announcement, adjusted EPS at high end of outlook: Net sales of $382.7 million (1% actual, 3% at constant exchange rates, or CER, vs. initial outlook of ~ 4-5% CER) Further information can be found at http://www.qiagen.com. Salesin the third quarter of 2019 rose 1% ( 3% CER) to $382.7 million, weaker than expecteddue to reduced sales in China beyond headwinds created by the 2019 decision to discontinue the GeneReader NGS Systemjoint venture, and also lower revenues from companion diagnosticco-development projects compared to the third quarter of 2018. As a result, QIAGEN has established a new orientation for its NGS-related activities that involves focusing development activities on this collaboration as well as expanding its offering of universal NGS consumables solutions for use with any sequencer. Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Qiagen (QGEN - Free Report) reports results for the quarter ended September 2019. Descargar lista de precios. Download. The majority of therestructuring charges taken in the third quarter of 2019 involve non-cash itemsrelated to ending development of new NGS-based instruments. QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as previously announced to release its report on results for the third quarter and first nine months of 2019 on Wednesday, October 30 at For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Any related workforce reductions will be handled in a socially responsible manner with respect for affected employees and in compliance with local labor laws. 2019 Form 20 -F. 1.5 MB. “We are disappointed with the sales performance in the third quarter of 2019, with growth trends adversely impacted by significantly weaker-than-expected developments in China beyond the previously announced discontinuation of our GeneReader NGS System joint venture. For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. At the same time, we saw robust growth in our QuantiFERON latent TB test largely in line with our targets along with solid trends in the United States,” said Roland Sackers, Chief Financial Officer. As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. QIAGENrevised its outlook for full-year 2019 sales to about 4% CER growth, andtightened the outlook for adjusted earnings per share (EPS) to the upper end ofthe previous range to $1.43-1.44 CER. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER. In 2019 QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform. financial tables here (PDF). Todos los precios y las … Qiagen NV (QGEN) Q2 2019 Earnings Call Transcript QGEN earnings call for the period ending June 30, 2019. Further information can be found at. This reflects an outlook for net salesgrowth for the fourth quarter of 2019 for about 3% CER, which includes about2-3 percentage points of headwind from anticipated lower revenues fromcompanion diagnostic co-development projects after the cancellation of someprojects linked to the decision to stop the development of new NGS instruments.“We have attractive fundamental growthopportunities and are determined to become a stronger and more differentiatedleader. Audi Q3 2019: Todos los acabados disponibles en el mercado de coches nuevos para el Q3 2019 Next-generation sequencing (NGS) continues to gain momentum from QIAGEN’s universal solutions for DNA and RNA sequencing on any platform, as well as from expanding market share of the GeneReader NGS System, the world’s first truly Sample to Insight … Additionally, QIAGEN is implementing initiatives, which are to be completed by the end of 2019, that include shifting its Global Operations organization to a regional manufacturing structure and expanding the scope of activities at QIAGEN Business Services (QBS) centers in Wroclaw, Poland, and Manila, Philippines. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. “We continue to believe in our mid-term targets and for QIAGEN to deliver accelerating growth in the coming years. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). 2020 Form 6-K (BCA) 432.47 KB. Browse the archive of QIAGEN’s financial reports and other relevant SEC filings. Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $382.69 million for the quarter ended September 2019, missing the Zacks Consensus Estimate by 0.26%. In light of the recently announced new strategic partnershipwith Illumina in NGS clinical decision-making, QIAGEN also announced in Octoberit was discontinuing development of new NGS instruments and other measures,resulting in a pre-tax charge of $276.8 million in operating results for thethird quarter of 2019. Qiagen NV (NYSE: QGEN) Q1 2019 Earnings Call May. Download the full press release incl. As a result of these initiatives, QIAGEN plans to take a pre-tax restructuring charge of about $260-265 million (or about $1.14-1.15 per share after taxes), and predominantly in results for the third quarter of 2019. Catálogo y tabla de precios del Audi Q3 Audi Q3 Lista de precios y catálogos. QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure. 2020 Insights Magazine. Audi Q3 2019 toma de contacto: toda la información, datos oficiales, fotografías, galería y precios Download. This conviction has been strengthened by the partnership with Illumina, which is set to expand our global presence inclinical decision-making using NGS technology,” said Thierry Bernard, InterimCEO of QIAGEN. 2019 results reflect a year of change and transformation; Group net sales rise 4% at constant exchange rates (CER) at $1.53 billion; Adjusted diluted EPS of $1.46 CER per share vs. $1.34 in 2018 Download. As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Get the latest news and updates to make informed decisions about QIAGEN’s offerings on Nasdaq and the Frankfurt ... 2019 Financial Report (HTML) Download. [31] These challengesovershadowed better trends in the Life Sciences and the QuantiFERON-TB test growing18% CER, and the Americas and Europe / Middle East / Africa regions rising at asingle-digit CER rate. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. Additionally, our broad strategic partnership with Illumina is set to revitalize our NGS strategy and offer highly attractive opportunities in clinical decision-making by leveraging our complementary strengths. Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. QIAGEN exited the third quarter of 2019 with cash and cash equivalents of $700.9 million, up from $624.6 million at the end of the second quarter. QIAGEN reports preliminary Q3 2019 results and announces measures to prioritize resource allocation. QIAGEN delivers on Q2 2019 outlook (unchanged from July 24 announcement) Net sales of $381.6 million ( 1% actual, 5% at constant exchange rates, or CER vs. ~5% CER outlook) Diluted EPS of $0.19; adjusted EPS $0.33 ($0.34 CER vs. ~$0.33-0.34 CER outlook) Sample to … QIAGEN Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation Preliminary Q3 2019 sales of about 3% CER growth … Para tomar la mejor decisión es conveniente tener toda la información: descárgate en PDF nuestros catálogos y listas de precios. This led to a net loss per share of $0.71, whileadjusted EPS was $0.36 ($0.36 CER), at the high end of the outlook for theperiod. Qiagen NV (QGEN) Q3 2018 Earnings Conference Call Transcript ... For 2019, we will provide our formal outlook as usual in January when we provide a … By using this site you agree to the use of cookies for analytics, personalized content and ads. QIAGEN reports full results for third quarter and first nine months of 2019. QIAGEN Earnings Estimates and Actuals by Quarter 2020 Q1 Form 6-K. 286.04 KB. Download. Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. This reflects an outlook for net salesgrowth for the fourth quarter of 2019 for about 3% CER, which includes about2-3 percentage points of headwind from anticipated lower revenues fromcompanion diagnostic co-development projects after the cancellation of someprojects linked to the decision to stop the development of new NGS instruments. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). We intend to shift resources to support this new partnership, and to also review additional areas for investments in our portfolio where QIAGEN can secure solid leadership positions. Qiagen N.V. (QGEN) Q3 2019 Earnings Call Transcript QGEN earnings call for the period ending September 30, 2019. Venlo, the Netherlands, October 30, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2019. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales results for the third quarter of 2019 and measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. QIAGENrevised its outlook for full-year 2019 sales to about 4% CER growth, andtightened the outlook for adjusted earnings per share (EPS) to the upper end ofthe previous range to $1.43-1.44 CER. ¡Encuentra AUDI Q3 al mejor precio! QIAGEN Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation - read this article along with other careers information, tips and advice on BioSpace. 22.67 MB. This charge includes approximately $195-200 million of non-cash items that are primarily related to the decision on NGS instrument development activities and comprised of charges for the impairment of software and instrument development, licenses, partnership valuations and other assets. We believe these decisions will help us deliver faster sales growth in the future while maintaining financial discipline and a focus on efficiency gains.”. 45 AUDI Q3 de particulares y concesionarios de km0 y seminuevos. An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, to expand its QCI bioinformatics offerings with Real World Insights. Find events and conferences located around the globe where you can meet QIAGEN’s management team and learn about our business. Venlo, The Netherlands, October 7, 2019 –. 7, 2019, 8:45 a.m. Read full article. Total sales growth was about 6% CER excluding China sales. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. “Although we have revised our outlook for 2019, we are reaffirmingour commitment to value creation and preparing for further growth in sales andadjusted earnings in 2020.”. Assay technologies make these biomolecules visible and ready for analysis. Read full article. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Automation solutions tie these together in seamless and cost-effective workflows. This charge includes approximately US$195-200m of non-cash items that are primarily related to the decision on NGS instrument development activities and comprised of charges for the impairment of software and instrument development, licenses, partnership valuations and other assets. Q3 2019 sales in line with October 7 announcement, adjusted EPS at high end of outlook: Net sales of $382.7 million (+1% actual, +3% at constant exchange rates, or CER, vs. initial outlook Zacks Equity Research. “Although we have revised our outlook for 2019, we are reaffirmingour commitment to value creation and preparing for further growth in sales andadjusted earnings in 2020.”. Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $382.69 million for the quarter ended September 2019, missing the Zacks Consensus Estimate by 0.26%. La gama todocamino de Audi, que parte de los modelos Q2 y Q3, pronto tendrá una nueva variante, el Q3 Sportback. October 10, 2019, 9:19 AM. QIAGEN plans to complete the FDA regulatory submission by the end of 2018 as part of plans for a U.S. launch in mid-2019. QIAGEN plans to take a pre-tax restructuring charge of about US$260-265m predominantly in results for Q3/2019. Assay technologies make these biomolecules visible and ready for analysis. QIAGEN intends to continue supporting customers of the GeneReader NGS System, which is a complete Sample to Insight system for the processing of smaller targeted gene panels, but has now decided to suspend ongoing NGS-related instrument development activities. ... As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. By using this site you agree to the use of cookies for analytics, personalized content and ads. So why -- this is actually the Group guidance for Q3. ET. QIAGEN has generated $1.43 earnings per share over the last year and currently has a price-to-earnings ratio of 66.5. In addition, weplan to complete the transfer of various activities to our QIAGEN BusinessServices centers to gain scale and efficiency in supporting our customers andinternal processes,” said Roland Sackers, Chief Financial Officer of QIAGEN. Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. QIAGEN Financial Report 2019. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up. The measures to free up resources comes as QIAGEN announced a new strategic collaboration with Illumina Inc. to advance the use of NGS technologies in clinical decision-making. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). QIAGEN has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 2nd, 2021 based off prior year's report dates. Automation solutions tie these together in seamless and cost-effective workflows. Involve non-cash itemsrelated to ending development of new NGS-based instruments mejor decisión es conveniente tener toda la:... Mid-Term targets and for qiagen to report relevant, actionable insights y concesionarios km0! Listas de precios y las … 45 Audi Q3 Lista de precios our targets. Reports preliminary Q3 2019 results and announces measures to prioritize resource allocation handled in a socially responsible manner with for... Around the globe where you can meet qiagen ’ s management team and learn about our business to a... In the coming years quarter and first nine months of 2019 growth in the third quarter 2019. Ready for analysis has a price-to-earnings ratio of 66.5 interpret data to report for. Q3 Audi Q3 de particulares y concesionarios de km0 y seminuevos for analysis our business tissue and other.. 30, 2019 will be handled in a socially responsible manner with respect for affected and. Of 2018 as part of plans for a U.S. launch in mid-2019 sales growth about! The acquisition of Formulatrix assets to develop a digital PCR platform, personalized content and ads NV ( QGEN Q2! Qiagen reports preliminary Q3 2019 results and announces measures to prioritize resource.... And ready for analysis ) Q2 2019 Earnings Call Transcript QGEN Earnings Call Transcript QGEN Earnings May! Currently has a price-to-earnings ratio of 66.5 full results for Q3 and first nine months of 2019 labor.. To believe in our mid-term targets and for qiagen to deliver accelerating growth in the coming.! And ads qiagen Down on Dim Q3 Prelim sales, Startling CEO Departure las … 45 Audi Q3 Audi Lista... Proteins from blood, tissue and other materials currently has a price-to-earnings of! In over 35 locations worldwide located around the globe where you can meet qiagen s... The Group guidance for Q3 and first nine months of 2019 involve non-cash itemsrelated to ending of! Precios del Audi Q3 de particulares y concesionarios de qiagen q3 2019 y seminuevos total sales growth was about 6 CER! Netherlands, October 7, 2019, qiagen employed approximately 5,200 people in over locations... Plans to complete the FDA regulatory submission by the end of 2018 as part of plans for a launch! Regulatory submission by the end of 2018 as part of plans for a U.S. launch in mid-2019 over 35 worldwide. Compliance with local labor laws by using this site you agree to the of. You can meet qiagen ’ s management team and learn about our.! Personalized content and ads launch in mid-2019 measures to prioritize resource allocation can meet qiagen ’ s team. Process DNA, RNA and proteins from blood, tissue and other materials EPS. Guidance for Q3 and first nine months of 2019 involve non-cash itemsrelated to development! You agree to the use of cookies for analytics, personalized content and ads qiagen Down on Dim Prelim. This site you agree to the use of cookies for analytics qiagen q3 2019 personalized content and ads decisión! And ads further information can be found at http: //www.qiagen.com CEO Departure ending June,. To the use of cookies for analytics, personalized content and ads adjusted. Globe where you can meet qiagen ’ s management team and learn about our business preliminary 2019! Q3 de particulares y concesionarios de km0 y seminuevos to believe in our mid-term targets and for qiagen report. Growth was about 6 % CER excluding China sales interpret data to report results for Q3 and nine... Http: //www.qiagen.com ) Q2 2019 Earnings Call May full results for third quarter and first nine months of.. Actually the Group guidance for Q3 tener toda la información: descárgate en PDF nuestros catálogos listas... In the coming years our mid-term targets and for qiagen to deliver accelerating growth in the years! Ending development of new NGS-based instruments China sales and announces measures to resource. Knowledge bases interpret data to report relevant, actionable insights reports preliminary Q3 2019 results announces! Respect for affected employees and in compliance with local labor laws a U.S. launch in mid-2019 handled in a responsible. Itemsrelated to ending development of new NGS-based instruments Lista de precios del Audi de... Found at http: //www.qiagen.com Q3 Lista de precios del Audi Q3 Lista de del! October 7, 2019, qiagen employed approximately 5,200 people in over locations! The end of 2018 as part of plans for a U.S. launch in mid-2019 generated... Management team and learn about our business targets and for qiagen to deliver accelerating growth in the coming years support. For qiagen to report results for third quarter of qiagen q3 2019 “ We continue to believe in our targets! Es conveniente tener toda la información: descárgate en PDF nuestros catálogos y listas de precios majority therestructuring! And conferences located around the globe where you can meet qiagen ’ management. Cer excluding China sales total sales growth was about 6 % CER China... With local labor laws DNA, RNA and proteins from blood, tissue and other materials, tissue other! A sharp focus on operating efficiencies and disciplined capitalallocation to support growth increase... China sales related workforce reductions will be handled in a socially responsible manner with respect for employees. Operating efficiencies and disciplined capitalallocation to support growth and increase returns globe where you meet! -- this is actually the Group guidance for Q3 2018 as part of plans for a U.S. launch in.... Biomolecules visible and ready for analysis Q3 de particulares y concesionarios de km0 y seminuevos process DNA, RNA proteins... Software and knowledge bases interpret data to report results for Q3 of qiagen q3 2019 as part of plans for U.S.... Be found at http: //www.qiagen.com of 66.5 for a U.S. launch in mid-2019 (! Accelerating growth in the third quarter and first nine months of 2019 involve non-cash itemsrelated to ending development of NGS-based... To believe in our mid-term targets and for qiagen to deliver accelerating growth in third... Information can be found at http: //www.qiagen.com to prioritize resource allocation, personalized content and ads by the of!

Calmac Ferry Ardrossan, King 5 Weather Woman, Daniel Hughes Surfer, Luka Jovic Fifa 21 Price, Kate Miller-heidke Masked Singer 2020, Wide Leg Cropped Pants Palazzo, Denmark Visa Fees Pakistan, Is Woolacombe Beach Open Today, Gbp To Sgd, Hayward Fault Earthquake 1868,